Market reviews 2012

Market review on human pharmaceuticals 2012

Published on 5 February 2013

According to statistics collected by Finnish Pharmaceutical Data Ltd, Finnish wholesale of human pharmaceuticals in 2012 totalled EUR 2,031 (1,972) million, up by 3% on the previous year.

Finland is the most important individual market for Orion, generating about one-quarter of the total net sales. Orion was able to increase its sales faster than the markets as a whole, so strengthened its position as leader in marketing pharmaceuticals in Finland. According to statistics collected by Finnish Pharmaceutical Data Ltd, Orion’s wholesale of human pharmaceuticals in Finland in 2012 amounted to EUR 219 (202) million, up by 9% compared with the previous year. Orion’s market share of Finnish pharmaceuticals markets was 11% (10%).

According According to IMS Health pharmaceutical sales statistics, in the 12-month period ending in September 2012 the total sales of Parkinson’s drugs in the United States were up by 3% at USD 751 million (USD 727 million in the previous 12-month period). The five largest European markets for Parkinson’s disease drugs were Germany, the United Kingdom, France, Spain and Italy. In these countries, the combined sales of Parkinson’s drugs in the 12-month period ending in September 2012 totalled EUR 954 (987) million, and the average market decline was 3%.

The most important individual therapy area for Orion is still the treatment of Parkinson’s disease. Orion’s Parkinson’s drugs account for about a quarter of the Group’s net sales. Sales of entacapone drugs in the United States remained stable, and in Japan sales continued to grow well and clearly better than the market as a whole. According to IMS Health pharmaceutical sales statistics, in the 12-month period ending in September 2012, sales of entacapone drugs in the United States totalled USD 195 million (USD 190 million in the previous 12-month period). Stalevo and Comtan accounted for 83% of these sales and generic entacapone products supplied by Orion accounted for 17%. Sales remained stable at a total of EUR 157 (157) million in the five largest markets in Europe, and were up by 23% at EUR 66 (53) million in Japan. The market share of entacapone drugs was 26% in the United States, on average 16% in the five largest European markets and 11% in Japan.

According to IMS Health pharmaceutical sales statistics, sales of Orion’s Precedex® intensive care sedative (dexmedetomidine) were up by 27% at USD 248 million in the 12-month period ending in September 2012 (USD 194 million in the previous 12-month period). About four-fifths of the sales amounting to USD 193 (153) million were in the United States, where Precedex sales grew by 27%.

Published on 23 October 2012

According to statistics collected by Finnish Pharmaceutical Data Ltd, Finnish wholesale of human pharmaceuticals in January–September 2012 totalled EUR 1,489 (1,453) million, up by 2% on the comparative period of the previous year.

Finland is the most important individual market for Orion, generating about one-quarter of the total net sales. Orion was able to increase its sales faster than the markets as a whole, so strengthened its position as leader in marketing pharmaceuticals in Finland. According to statistics collected by Finnish Pharmaceutical Data Ltd, Orion’s wholesale of human pharmaceuticals in Finland in January–September amounted to EUR 162 (150) million, up by 8% compared with the corresponding period in the previous year. Orion’s market share of Finnish pharmaceuticals markets was 11% (10%).

According According to IMS Health pharmaceutical sales statistics, in the 12-month period ending in June 2012 the total sales of Parkinson’s drugs in the United States were down by 11% at USD 679 million (USD 760 million in the previous 12-month period). The decrease in in-market sales was due to commencement of generic competition in certain products. The five largest European markets for Parkinson’s disease drugs were Germany, the United Kingdom, France, Spain and Italy. In these countries, the combined sales of Parkinson’s drugs in the 12-month period ending in June 2012 totalled EUR 952 (1,014) million, and the average market decline was 6%.

The most important individual therapy area for Orion is still the treatment of Parkinson’s disease. Orion’s Parkinson’s drugs account for about a quarter of the Group’s net sales. Sales of entacapone drugs in the United States remained stable despite a clear decrease in the market as a whole. In Japan sales continued to grow well and clearly better than the market as a whole. According to IMS Health pharmaceutical sales statistics, in the 12-month period ending in June 2012, sales of entacapone drugs in the United States totalled USD 182 million (USD 181 million in the previous 12-month period). Stalevo and Comtan accounted for 92% of these sales and generic entacapone products supplied by Orion accounted for 8%. Sales remained stable at a total of EUR 157 (158) million in the five largest markets in Europe, and up by 21% at EUR 62 (52) million in Japan. The market share of entacapone drugs was 27% in the United States, on average 17% in the five largest European markets and 11% in Japan.

According to IMS Health pharmaceutical sales statistics, sales of Orion’s Precedex® intensive care sedative (dexmedetomidine) were up by 27% at USD 230 million in the 12-month period ending in June 2012 (USD 180 million in the previous 12-month period). About four-fifths of the sales amounting to USD 178 (146) million were in the United States, where Precedex sales grew by 22%.

Published on 31 July 2012

According to statistics collected by Finnish Pharmaceutical Data Ltd, Finnish wholesale of human pharmaceuticals in January–June 2012 totalled EUR 1,000 (967) million, up by 3% on the comparative period of the previous year.

Finland is the most important individual market for Orion, generating about one-quarter of the total net sales. Orion was able to increase its sales faster than the markets as a whole, so strengthened its position as leader in marketing pharmaceuticals in Finland. According to statistics collected by Finnish Pharmaceutical Data Ltd, Orion’s wholesale of human pharmaceuticals in Finland in January–June amounted to EUR 108 (100) million, up by 8% compared with comparative period of the previous year. Orion’s market share of Finnish pharmaceuticals markets was 11% (10%).

According to IMS Health pharmaceutical sales statistics, in the 12-month period ending in March 2012 the total sales of Parkinson’s drugs in the United States were down by 21% at USD 664 million (USD 838 million in the previous 12-month period). The decrease in in-market sales was due to commencement of generic competition in certain products. The five largest European markets for Parkinson’s disease drugs were Germany, the United Kingdom, France, Spain and Italy. In these countries, the combined sales of Parkinson’s drugs in the 12-month period ending in March 2012 totalled EUR 951 (1,033) million, and the average market decline was 8%.

The most important individual therapy area for Orion is still the treatment of Parkinson’s disease. Orion’s Parkinson’s drugs account for about a quarter of the Group’s net sales. Sales of Orion’s Parkinson’s drugs in the United States remained stable despite a clear decrease in the market as a whole. In Japan sales continued to grow well and clearly better than the market as a whole. According to IMS Health pharmaceutical sales statistics, in the 12-month period ending in March 2012, sales of Orion’s Parkinson’s drugs in the United States totalled USD 180 million (USD 180 million in the previous 12-month period). Sales remained stable at a total of EUR 157 (158) million in the five largest markets in Europe, and up by 16% at EUR 58 (50) million in Japan. The market share of Orion’s Parkinson’s drugs was 27% in the United States, on average 16% in the five largest European markets and 11% in Japan.
Markets for Precedex, the sedative agent

According to IMS Health pharmaceutical sales statistics, sales of Orion’s Precedex® intensive care sedative (dexmedetomidine) were up by 28% at USD 217 million in the 12-month period ending in March 2012 (USD 158 million in the previous 12-month period). About four-fifths of the sales amounting to USD 168 (141) million were in the United States, where Precedex sales grew by 19%.

Published on 24 April 2012

According to statistics collected by Finnish Pharmaceutical Data Ltd, Finnish wholesale of human pharmaceuticals in January–March 2012 totalled EUR 493 (474) million, up by 4% on the comparative period of the previous year.

Finland is the most important individual market for Orion, generating about one-quarter of the total net sales. Orion was able to increase its sales faster than the markets as a whole, so strengthened its position as leader in marketing pharmaceuticals in Finland. According to statistics collected by Finnish Pharmaceutical Data Ltd, Orion’s wholesale of human pharmaceuticals in Finland in January–March amounted to EUR 54 (49) million, up by 10% compared with comparative period of the previous year. Orion’s market share of Finnish pharmaceuticals markets was 11% (10%).

According to IMS Health pharmaceutical sales statistics, in the 12-month period ending in December 2011 the total sales of Parkinson’s drugs in the United States were down by 28% at USD 669 million (USD 922 million in the previous 12-month period). The decrease in in-market sales was due to commencement of generic competition in certain products. The five largest European markets for Parkinson’s disease drugs were Germany, the United Kingdom, France, Spain and Italy. In these countries, the combined sales of Parkinson’s drugs in the 12-month period ending in December 2011 totalled EUR 955 (1,043) million, and the average market decline was 8%.

The most important individual therapy area for Orion is still the treatment of Parkinson’s disease. Orion’s Parkinson’s drugs account for one-quarter of the Group’s net sales. Sales of Orion’s Parkinson’s drugs in the United States remained stable despite a clear decrease in the market as a whole. In Japan sales continued to grow well and clearly better than the market as a whole. According to IMS Health pharmaceutical sales statistics, in the 12-month period ending in December 2011, sales of Orion’s Parkinson’s drugs in the United States totalled USD 181 (USD 180 million in the previous 12-month period) million. Sales remained stable at a total of EUR 156 (158) million in the five largest markets in Europe, and up by 18% at EUR 56 (47) million in Japan. The market share of Orion’s Parkinson’s drugs was 27% in the United States, on average 16% in the five largest European markets and 11% in Japan.

According to IMS Health pharmaceutical sales statistics, sales of Orion’s Precedex® intensive care sedative (dexmedetomidine) were up by 33% at USD 206 million in the 12-month period ending in December 2011 (USD 155 million in the previous 12-month period). About four-fifths of the sales amounting to USD 161 (132) million were in the United States, where Precedex sales grew by 22%.